Point72 Middle East FZE’s RxSight RXST Stock Holding History

Point72 Middle East FZE’s Portfolio RXST Stock Details RXST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-394	Closed	-$4.99K	–	2123
2022 Q4	$4.99K	Buy	+394	New	+$4.79K	﹤0.01%	1777

Other funds holding RXST

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCGI

Next Century Growth Investors Plymouth, Minnesota $1.38B AUM 102.34% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

PHP

Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return

Point72 Middle East FZE's RXST Position: Q1 2023 in Review

Point72 Middle East FZE sold out of RxSight (RXST) in Q1 2023, closing a stake of 394 shares — an estimated $4.99K sold.

Point72 Middle East FZE first reported a position in RXST in Q4 2022 and held it in 1 quarter. The position peaked at $4.99K in Q4 2022. 74 funds tracked by Wall St. Rank hold RXST as of Q1 2023.

Point72 Middle East FZE reported no remaining RxSight position as of Q1 2023 after selling out during the quarter.
Point72 Middle East FZE sold 394 RxSight shares in Q1 2023, an estimated $4.99K.
Point72 Middle East FZE first reported a position in RxSight in Q4 2022 and held it in 1 quarter.
Point72 Middle East FZE's RxSight position peaked at $4.99K in Q4 2022.
74 funds tracked by Wall St. Rank held RxSight as of Q1 2023.

Based on Point72 Middle East FZE's 13F filing for Q1 2023, filed 15 May 2023.